HUE051774T2 - Oszteoprotektív géneket, például HAS2-t és lubricint expresszáló rekombináns AAV vektorok, amelyek alkalmazhatók emlõsben oszteoartritisz és azzal kapcsolatos ízületi állapotok kezelésében - Google Patents

Oszteoprotektív géneket, például HAS2-t és lubricint expresszáló rekombináns AAV vektorok, amelyek alkalmazhatók emlõsben oszteoartritisz és azzal kapcsolatos ízületi állapotok kezelésében

Info

Publication number: HUE051774T2
Authority: HU; Hungary
Prior art keywords: osteoprotective; lubricin; has2; osteoarthritis; mammals
Prior art date: 2016-01-13

Application number

HUE17705715A

Other languages

English (en)

Inventor

Figueiredo Monica Dias

Sirkka Kyostio-Moore

Patricia Berthelette

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-13

Filing date

2017-01-13

Publication date

2021-03-29

2017-01-13 Application filed by Genzyme Corp filed Critical Genzyme Corp

2021-03-29 Publication of HUE051774T2 publication Critical patent/HUE051774T2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01212—Hyaluronan synthase (2.4.1.212)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Biophysics (AREA)
Virology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Orthopedic Medicine & Surgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

HUE17705715A 2016-01-13 2017-01-13 Oszteoprotektív géneket, például HAS2-t és lubricint expresszáló rekombináns AAV vektorok, amelyek alkalmazhatók emlõsben oszteoartritisz és azzal kapcsolatos ízületi állapotok kezelésében HUE051774T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662278243P	2016-01-13	2016-01-13

Publications (1)

Publication Number	Publication Date
HUE051774T2 true HUE051774T2 (hu)	2021-03-29

Family

ID=58054500

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE17705715A HUE051774T2 (hu)	2016-01-13	2017-01-13	Oszteoprotektív géneket, például HAS2-t és lubricint expresszáló rekombináns AAV vektorok, amelyek alkalmazhatók emlõsben oszteoartritisz és azzal kapcsolatos ízületi állapotok kezelésében

Country Status (16)

Country	Link
US (3)	US20170198263A1 (hu)
EP (2)	EP3402530B1 (hu)
JP (2)	JP7058603B2 (hu)
KR (1)	KR20180095720A (hu)
CN (2)	CN108697813B (hu)
AR (1)	AR108683A1 (hu)
AU (2)	AU2017207917B2 (hu)
CA (1)	CA3011459A1 (hu)
CY (1)	CY1123760T1 (hu)
DK (1)	DK3402530T3 (hu)
ES (1)	ES2835031T3 (hu)
HU (1)	HUE051774T2 (hu)
MX (2)	MX2018008651A (hu)
RU (1)	RU2771490C2 (hu)
WO (1)	WO2017123934A1 (hu)
ZA (1)	ZA201804731B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2966620A1 (en)	2014-11-05	2016-05-12	Voyager Therapeutics, Inc.	Aadc polynucleotides for the treatment of parkinson's disease
EP3230441A4 (en)	2014-12-12	2018-10-03	Voyager Therapeutics, Inc.	Compositions and methods for the production of scaav
JOP20190269A1 (ar)	2017-06-15	2019-11-20	Voyager Therapeutics Inc	بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN109055426B (zh) *	2018-08-06	2021-06-25	智享生物(苏州)有限公司	一种在中华仓鼠卵巢细胞中表达生产类人润滑素的方法
WO2020150396A1 (en) *	2019-01-15	2020-07-23	Cornell University	Recombinant lubricins, and compositions and methods for using the same
CN113557036A (zh) *	2019-01-18	2021-10-26	奥泽生物疗法公司	基因编辑以改善关节功能
CA3162235A1 (en) *	2019-11-21	2021-05-27	Remedium Bio, Inc.	Growth factor restoration
KR102584136B1 (ko) *	2020-01-17	2023-10-04	주식회사 아바테라퓨틱스	조직 재생용 조성물
WO2022232129A1 (en) *	2021-04-26	2022-11-03	University Of Massachusetts	Capsid variants and uses thereof
CN114457086B (zh) *	2022-03-02	2022-11-15	上海勉亦生物科技有限公司	白介素1受体拮抗蛋白的表达盒以及基于aav的基因递送系统
KR20230152503A (ko) *	2022-04-27	2023-11-03	주식회사 헬릭스미스	척수강 내 투여에 최적화 된 간세포 성장인자 유전자가 도입된 aav 벡터
CN117721152B (zh) *	2023-12-29	2024-08-30	广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院）	Ttp在制备骨关节炎药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4797368A (en)	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
US5328470A (en)	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5693531A (en)	1993-11-24	1997-12-02	The United States Of America As Represented By The Department Of Health And Human Services	Vector systems for the generation of adeno-associated virus particles
US5658785A (en)	1994-06-06	1997-08-19	Children's Hospital, Inc.	Adeno-associated virus materials and methods
US6423514B1 (en)	1996-04-22	2002-07-23	Millennium Pharmaceuticals, Inc.	Mammalian hyaluronan synthases, nucleic acids and uses thereof
US6566118B1 (en)	1997-09-05	2003-05-20	Targeted Genetics Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en)	1997-09-05	2006-01-24	Targeted Genetics Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6743774B1 (en)	1999-04-23	2004-06-01	Rhode Island Hospital	Tribonectins
US6315992B1 (en) *	1999-06-30	2001-11-13	Tissuegene Co.	Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1
US7338655B1 (en) *	1999-06-30	2008-03-04	Tissuegene, Inc.	Gene therapy using TGF-β
ES2478635T3 (es) *	1999-08-09	2014-07-22	Targeted Genetics Corporation	Incremento de la expresión de una secuencia de nucleótidos heteróloga monocatenaria de vectores virales recombinantes diseñando la secuencia de modo que forma pares de bases intracatenarios
JP2003164289A (ja) *	2001-11-30	2003-06-10	Seikagaku Kogyo Co Ltd	骨組織導入用遺伝子
US7618914B2 (en)	2003-02-14	2009-11-17	Wako Pure Chemical Industries, Ltd.	Method for producing hydroxylamine compound using platinum catalyst fixed on ion-exchange resin
US20060240037A1 (en)	2003-06-04	2006-10-26	Edward Fey	Methods and compositions for the treatment and prevention of degenerative joint disorders
CN102924584A (zh) *	2003-08-14	2013-02-13	惠氏公司	重组润滑素分子及其用途
NZ545656A (en) *	2003-09-01	2009-02-28	Amc Amsterdam	AAV vectors for in vivo gene therapy of rheumatoid arthritis
JP4863874B2 (ja)	2003-09-01	2012-01-25	アカデミッシュメディッシュセントラム	関節リウマチのインビボ遺伝子治療のためのａａｖベクター
US20090155200A1 (en)	2004-04-20	2009-06-18	Jay Gregory D	Methods of promoting cartilage healing or cartilage integration
US20080139458A1 (en)	2004-12-03	2008-06-12	Jay Gregory D	Methods of Treatment For Injured or Diseased Joints
US7771995B2 (en)	2005-11-14	2010-08-10	Merial Limited	Plasmid encoding human BMP-7
WO2007127428A2 (en) *	2006-04-28	2007-11-08	University Of Florida Research Foundation, Inc.	Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
US20080187576A1 (en) *	2006-06-16	2008-08-07	University Of Florida Research Foundation, Inc.	Methods for treating articular disease or dysfunction using self-complimentary adeno-associated viral vectors
ES2714007T3 (es)	2007-04-09	2019-05-24	Univ Florida	Composiciones de vectores rAAV que tienen proteínas de la cápside modificadas en tirosina y métodos para su uso
US7846428B2 (en)	2007-10-05	2010-12-07	Merial Limited	Articular cartilage gene therapy with recombinant vector encoding BMP-7
KR101828421B1 (ko) *	2007-12-04	2018-02-12	프로테오바이오엑티브스 피티와이 엘티디	전구 세포의 보호 및 그의 분화 조절
WO2010115841A1 (en)	2009-04-01	2010-10-14	Galapagos Nv	Methods and means for treatment of osteoarthritis
WO2011005493A2 (en)	2009-06-22	2011-01-13	Mayo Foundation For Medical Education And Research	Methods and materials for tissue repair
CA2788682C (en) *	2010-02-05	2019-03-05	The University Of North Carolina At Chapel Hill	Compositions and methods for enhanced parvovirus transduction
RU2015134562A (ru) *	2011-02-08	2018-12-24	Эббви Инк.	Лечение остеоартрита и боли
US20130116186A1 (en)	2011-10-04	2013-05-09	Rhode Island Hospital, A Lifespan Partner	Lubricin injections to maintain cartilage health
PL2623604T3 (pl)	2012-02-02	2015-07-31	Baylor College Medicine	Biologiczny system dostarczania i ekspresji oparty na adenowirusie do zastosowania w leczeniu choroby zwyrodnieniowej stawów
WO2013151663A1 (en) *	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of membrane proteins
EP2948553B1 (en) *	2013-01-25	2020-04-01	Baylor College Of Medicine	A helper-dependent adenoviral gene therapy delivery and expression system
WO2014205237A2 (en) *	2013-06-19	2014-12-24	University Of Rochester	Compositions and methods for use of high molecular weight hyaluronic acid for cancer therapy
WO2015035395A1 (en) *	2013-09-09	2015-03-12	Figene, Llc	Gene therapy for the regeneration of chondrocytes or cartilage type cells
US20170304466A1 (en) *	2014-10-06	2017-10-26	Arthrogen B.V.	AAV-Based Gene Therapy

2017
- 2017-01-13 HU HUE17705715A patent/HUE051774T2/hu unknown
- 2017-01-13 EP EP17705715.5A patent/EP3402530B1/en active Active
- 2017-01-13 KR KR1020187023241A patent/KR20180095720A/ko not_active Application Discontinuation
- 2017-01-13 EP EP20175445.4A patent/EP3769788A1/en active Pending
- 2017-01-13 ES ES17705715T patent/ES2835031T3/es active Active
- 2017-01-13 MX MX2018008651A patent/MX2018008651A/es unknown
- 2017-01-13 RU RU2018129159A patent/RU2771490C2/ru active
- 2017-01-13 CN CN201780012912.2A patent/CN108697813B/zh active Active
- 2017-01-13 WO PCT/US2017/013419 patent/WO2017123934A1/en active Application Filing
- 2017-01-13 AR ARP170100101A patent/AR108683A1/es unknown
- 2017-01-13 AU AU2017207917A patent/AU2017207917B2/en active Active
- 2017-01-13 CN CN202410173883.XA patent/CN118048321A/zh active Pending
- 2017-01-13 CA CA3011459A patent/CA3011459A1/en active Pending
- 2017-01-13 US US15/405,992 patent/US20170198263A1/en not_active Abandoned
- 2017-01-13 JP JP2018536882A patent/JP7058603B2/ja active Active
- 2017-01-13 DK DK17705715.5T patent/DK3402530T3/da active
2018
- 2018-07-12 MX MX2021004397A patent/MX2021004397A/es unknown
- 2018-07-16 ZA ZA2018/04731A patent/ZA201804731B/en unknown
2019
- 2019-07-29 US US16/524,645 patent/US11905531B2/en active Active
2020
- 2020-11-19 CY CY20201101100T patent/CY1123760T1/el unknown
2022
- 2022-01-13 JP JP2022003580A patent/JP2022058602A/ja active Pending
2024
- 2024-01-08 US US18/407,298 patent/US20240254454A1/en active Pending
- 2024-06-07 AU AU2024203920A patent/AU2024203920A1/en active Pending

Also Published As

Publication number	Publication date
CA3011459A1 (en)	2017-07-20
US20200231940A1 (en)	2020-07-23
EP3769788A1 (en)	2021-01-27
RU2018129159A3 (hu)	2020-03-27
CY1123760T1 (el)	2022-03-24
ES2835031T3 (es)	2021-06-21
JP7058603B2 (ja)	2022-04-22
MX2018008651A (es)	2019-03-14
EP3402530A1 (en)	2018-11-21
CN108697813B (zh)	2024-01-16
KR20180095720A (ko)	2018-08-27
JP2022058602A (ja)	2022-04-12
CN108697813A (zh)	2018-10-23
RU2018129159A (ru)	2020-02-13
US11905531B2 (en)	2024-02-20
RU2771490C2 (ru)	2022-05-05
CN118048321A (zh)	2024-05-17
ZA201804731B (en)	2019-05-29
WO2017123934A1 (en)	2017-07-20
EP3402530B1 (en)	2020-08-19
US20170198263A1 (en)	2017-07-13
AU2024203920A1 (en)	2024-07-11
DK3402530T3 (da)	2020-11-23
AU2017207917A1 (en)	2018-08-16
AU2017207917B2 (en)	2024-03-07
AR108683A1 (es)	2018-09-19
MX2021004397A (es)	2021-06-08
US20240254454A1 (en)	2024-08-01
JP2019506859A (ja)	2019-03-14

Publication	Publication Date	Title
ZA201804731B (en)	2019-05-29	Recombinant aav vectors expressing osteoprotective genes, including has2 and lubricin, useful in the treatment of osteoarthritis and related joint conditions in mammals
IL274218A (en)	2020-06-30	Adenovirus vectors and their uses
IL259877A (en)	2018-07-31	Adeno-type viral vectors used to treat spinal muscular atrophy
SG10202110491PA (en)	2021-11-29	Nucleic acids encoding crispr-associated proteins and uses thereof
IL282885A (en)	2021-06-30	AAV viral vectors and their uses
ZA201606763B (en)	2023-05-31	Aav vectors for retinal and cns gene therapy
LT3197472T (lt)	2021-11-10	Rekombinantinių baltymų be fenilalanino naudojimas gydant fenilketonuriją
IL256630B (en)	2022-10-01	Combined separator and coagulator
SG11202009009UA (en)	2020-10-29	Viral and non-viral nanoplasmid vectors with improved production
IL304733A (en)	2023-09-01	Improved use of botulinum toxin to treat sialorrhea
ZA201704726B (en)	2019-01-30	Peptides and their use in the treatment of skin
IL253103A0 (en)	2017-08-31	Adeno-associated viral vectors encoding adapted g6pc and uses thereof
HK1253863A1 (zh)	2019-07-05	含prrsv次要蛋白的重組病毒載體及其製造方法與用途
IL261397A (en)	2018-10-31	Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
IL259096A (en)	2018-06-28	Peptides and methods of treating endometriosis using the same
IL271404A (en)	2020-01-30	Strains for improved protein expression
IL265236A (en)	2019-05-30	Multipurpose medical buildings and their uses
IL277734A (en)	2020-11-30	Application of short PEDF-derived peptides in the treatment of osteoarthritis
IL269751A (en)	2019-11-28	CLPB-derived proteins and their uses
HK1209363A1 (en)	2016-04-01	Use of lactobacillus crispatus in the treatment or prevention of rheumatoid arthritis or related diseases
PT3250234T (pt)	2020-04-06	Mdv1 recombinante e suas utilizações
IL268844A (en)	2019-10-31	Peptides and methods of treating dystrophy-related diseases by them
GB201619551D0 (en)	2017-01-04	Prokaryotic Argonaute proteins and uses thereof
GB201612090D0 (en)	2016-08-24	Prokaryotic argonaute proteins and uses thereof